Idenix: J.P. Morgan Healthcare Conference (Idenix) - Jan 9, 2013 - Anticipated initiation of 12-week P2 (DAA combo) trial for HCV in H1 2013; Anticipated initiation of P3 (DAA combo) trial for HCV in 2014; Anticipated initiation of P2 (nuc combo) trial for HCV in 2014; Anticipated initiation of P3 (nuc combo) trial for HCV in 2015; Anticipated completion of 12-week P2 (DAA combo) trial for HCV in H1 2014; Anticipated completion of P3 (DAA combo) trial for HCV in 2016; Anticipated completion of P2 (nuc combo) trial for HCV in 2014/2015; Anticipated completion of P3 (nuc combo) trial for HCV in 2016
Anticipated new P2 trial • Anticipated new P3 trial • Anticipated trial completion date • Hepatitis C Virus
|